Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of A-dmDT390-bisFv(UCHT1) Fusion Protein in Patients With Cutaneous T Cell Lymphoma

NCT00611208 is registered in ClinicalTrials.gov with Virogen Biotechnology Inc. as lead sponsor.

NCT NCT00611208
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00611208 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of A-dmDT390-bisFv(UCHT1) Fusion Protein in Patients With Cutaneous T Cell Lymphoma
Lead sponsor
Virogen Biotechnology Inc.
Phase
Phase 2
Overall status
Completed
Start date
January 31, 2008
Completion date
November 30, 2016
Enrollment
32 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

cutaneous t-cell lymphoma (ctcl), mycosis fungoides, sezary syndrome, t-cell leukemia, t-cell lymphomas